Allovir IncNASDAQ:ALVRNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.7990
- TODAY'S CHANGE (%)0.0177 (2.2655%)
- Bid / Lots0.7703/ 13
- Ask / Lots0.7996/ 35
- Open / Previous Close0.7900 / 0.7813
- Day Range
- 52 Week Range
- Volume259,455
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ALVR |
|---|---|---|
| 09:32 ET | 123 | 0.79 |
| 09:48 ET | 132 | 0.7605 |
| 10:03 ET | 100 | 0.7897 |
| 10:10 ET | 400 | 0.7897 |
| 10:12 ET | 100 | 0.771 |
| 10:21 ET | 721 | 0.771 |
| 10:24 ET | 2935 | 0.7813 |
| 10:26 ET | 20624 | 0.7878 |
| 10:28 ET | 200 | 0.7789 |
| 10:30 ET | 125 | 0.7878 |
| 10:33 ET | 300 | 0.7878 |
| 10:35 ET | 100 | 0.7879 |
| 10:42 ET | 1500 | 0.7735 |
| 10:48 ET | 750 | 0.7807 |
| 10:50 ET | 100 | 0.7879 |
| 10:57 ET | 855 | 0.78325 |
| 11:00 ET | 5000 | 0.789799 |
| 11:02 ET | 31089 | 0.79 |
| 11:04 ET | 32959 | 0.79 |
| 11:06 ET | 2812 | 0.7908 |
| 11:08 ET | 100 | 0.7908 |
| 11:09 ET | 1776 | 0.7908 |
| 11:13 ET | 8800 | 0.7908 |
| 11:15 ET | 600 | 0.8 |
| 11:18 ET | 530 | 0.7908 |
| 11:20 ET | 550 | 0.7908 |
| 11:22 ET | 150 | 0.7817 |
| 11:24 ET | 6559 | 0.7908 |
| 11:29 ET | 200 | 0.79075 |
| 11:31 ET | 700 | 0.79075 |
| 11:40 ET | 200 | 0.799 |
| 11:42 ET | 602 | 0.7998 |
| 11:45 ET | 200 | 0.7908 |
| 11:47 ET | 600 | 0.79075 |
| 11:49 ET | 902 | 0.79 |
| 11:51 ET | 100 | 0.78585 |
| 11:54 ET | 100 | 0.79 |
| 11:58 ET | 300 | 0.79 |
| 12:00 ET | 9200 | 0.7817 |
| 12:03 ET | 432 | 0.7859 |
| 12:05 ET | 100 | 0.7859 |
| 12:07 ET | 300 | 0.79 |
| 12:09 ET | 100 | 0.79 |
| 12:14 ET | 100 | 0.7899 |
| 12:16 ET | 300 | 0.7899 |
| 12:18 ET | 238 | 0.7899 |
| 12:21 ET | 450 | 0.7899 |
| 12:23 ET | 100 | 0.7819 |
| 12:25 ET | 2200 | 0.79 |
| 12:34 ET | 300 | 0.7862 |
| 12:39 ET | 200 | 0.7903 |
| 12:41 ET | 300 | 0.7904 |
| 12:48 ET | 399 | 0.79 |
| 12:50 ET | 100 | 0.7862 |
| 12:54 ET | 300 | 0.7903 |
| 12:57 ET | 100 | 0.7903 |
| 01:01 ET | 400 | 0.7903 |
| 01:03 ET | 300 | 0.7903 |
| 01:14 ET | 100 | 0.78625 |
| 01:15 ET | 1038 | 0.7903 |
| 01:17 ET | 100 | 0.7902 |
| 01:19 ET | 1420 | 0.7903 |
| 01:24 ET | 100 | 0.7831 |
| 01:26 ET | 200 | 0.7903 |
| 01:33 ET | 703 | 0.79 |
| 01:35 ET | 100 | 0.7904 |
| 01:37 ET | 100 | 0.7905 |
| 01:39 ET | 100 | 0.7887 |
| 01:42 ET | 300 | 0.7905 |
| 01:50 ET | 1563 | 0.7934 |
| 01:51 ET | 147 | 0.7933 |
| 01:57 ET | 300 | 0.7997 |
| 02:00 ET | 200 | 0.7933 |
| 02:06 ET | 100 | 0.7997 |
| 02:09 ET | 100 | 0.7933 |
| 02:15 ET | 563 | 0.7933 |
| 02:20 ET | 301 | 0.7933 |
| 02:24 ET | 300 | 0.7997 |
| 02:29 ET | 100 | 0.7933 |
| 02:33 ET | 100 | 0.7996 |
| 02:36 ET | 400 | 0.7997 |
| 02:38 ET | 289 | 0.787 |
| 02:40 ET | 200 | 0.7948 |
| 02:42 ET | 200 | 0.7933 |
| 02:44 ET | 100 | 0.7933 |
| 02:47 ET | 1089 | 0.7996 |
| 02:54 ET | 200 | 0.7996 |
| 02:56 ET | 18500 | 0.79 |
| 03:00 ET | 302 | 0.7868 |
| 03:03 ET | 1000 | 0.7868 |
| 03:05 ET | 5802 | 0.783 |
| 03:09 ET | 5000 | 0.7903 |
| 03:16 ET | 5300 | 0.78685 |
| 03:18 ET | 100 | 0.7913 |
| 03:21 ET | 5356 | 0.7902 |
| 03:25 ET | 600 | 0.7869 |
| 03:27 ET | 200 | 0.7869 |
| 03:30 ET | 100 | 0.7915 |
| 03:32 ET | 348 | 0.7916 |
| 03:36 ET | 552 | 0.7822 |
| 03:43 ET | 1630 | 0.7841 |
| 03:48 ET | 22718 | 0.7916 |
| 03:50 ET | 21143 | 0.786 |
| 03:52 ET | 800 | 0.7899 |
| 03:57 ET | 8067 | 0.7948 |
| 03:59 ET | 6136 | 0.799 |
Sep 16, 2024
Kuehn Law Encourages Investors of AlloVir, Inc. to Contact Law Firm, from 11:16AM ET on Monday Sep 16, 2024 by Dow Jones
11:16AM ET on Monday Sep 16, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Allovir Inc | 90.1M | -0.7x | --- |
Hillevax Inc | 89.1M | -0.5x | --- |
Benitec Biopharma Inc | 88.7M | -0.9x | --- |
Citius Pharmaceuticals Inc | 93.4M | -2.1x | --- |
Genenta Science SPA | 74.5M | -5.5x | --- |
ALX Oncology Holdings Inc | 98.5M | -0.5x | --- |
Company Information
AlloVir, Inc. is an allogeneic T cell immunotherapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The company’s proprietary technology platforms leverage off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. Its technology and manufacturing process enable the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. Its lead product candidate, posoleucel, is a multi-VST therapy that targets six viruses: adenovirus (BKV), cytomegalovirus (EBV), human herpesvirus 6 (HHV-6) and JC virus (JCV). Its proprietary VST manufacturing platform enables the rapid, robust and reproducible generation of single-virus and multi-virus specific cell therapeutic candidates for clinical use.
Contact Information
- Headquarters
- 1100 Winter StreetWALTHAM, MA, United States 02451
- Phone
- 617-433-2605
- Fax
- 302-655-5049
Executives
- Executive Chairman of the Board
- David Hallal
- President, Chief Financial Officer, Director
- Vikas Sinha
- Chief Executive Officer, Director
- Diana Brainard
- Co-Founder, Chief Scientific Officer
- Ann Leen
- Chief Accounting Officer
- Brett Hagen
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $90.1M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 115.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.78 |
EPS | $-1.23 |
Book Value | $1.28 |
P/E Ratio | -0.7x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
